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The use of central venous catheters (CVCs) in children is escalating, which is likely linked 
to the increased incidence of pediatric venous thromboembolism (VTE). In order to bet-
ter understand the specific risk factors associated with CVC-VTE in children, as well as 
available prevention methods, a literature review was performed. The overall incidence 
of CVC-VTE was found to range from 0 to 74%, depending on the patient population, 
CVC type, imaging modality, and study design. Throughout the available literature, there 
was not a consistent determination regarding whether a particular type of central line 
(tunneled vs. non-tunneled vs. peripherally inserted vs. implanted), catheter material, 
insertion technique, or insertion location lead to an increased VTE risk. The patient 
populations who were found to be most at risk for CVC-VTE were those with cancer, 
congenital heart disease, gastrointestinal failure, systemic infection, intensive care unit 
admission, or involved in a trauma. Both mechanical and pharmacological prophylactic 
techniques have been shown to be successful in preventing VTE in adult patients, but 
studies in children have yet to be performed or are underpowered. In order to better 
determine true CVC-VTE risk factors and best preventative techniques, an increase in 
large, prospective pediatric trials needs to be performed.
Keywords: central venous catheter, pediatric, venous thromboembolism, venous thrombosis, thromboprophylaxis, 
tunneled line, peripherally inserted central catheter
inTRODUCTiOn
Central venous catheters (CVCs) are the single largest risk factor for pediatric venous thromboem-
bolism (VTE) in all pediatric populations. The incidence of VTE in children is increasing, most likely 
secondary to advances in care of critically ill children and the increased insertion rate of CVCs (1). 
The use of CVCs has risen over the past decade due to their relative ease in placement and necessity 
for many lifesaving treatments, but this increase will likely lead to further escalating rates of pediatric 
VTE. CVCs can lead to VTE by causing vascular injury during insertion, as well as causing turbu-
lent blood flow while the catheter is laying in the vessel lumen, with 85% of pediatric VTEs being 
CVC related (2, 3). Studies have been performed to evaluate catheter types, insertion locations, and 
catheter sizes that may lead to the highest probability of VTE. Most studies focus on limited patient 
populations, such as infants and patients in the intensive care setting or malignancy. Unfortunately, 
at this time, there are no guidelines in pediatric patients on how to choose the best central catheter 
type or insertion technique or prevention modalities to decrease the occurrence of VTE. CVC fail-
ures may be attributed to chemical or mechanical obstructions or VTE. This manuscript will review 
TABLe 1 | Characteristics of CvC that may cause an increased incidence 
of vTe in children.
CvC characteristic associated with increased vTe incidence Reference
Externally tunneled CVCs (vs. internal CVCs, such as port-a-caths) (9)
CVCs placed in the femoral vein (vs. upper extremity) (10, 11)
CVCs placed on the upper left side, in the subclavian vein  
(vs. jugular), and percutaneous technique (vs. cut-down)
(11, 12)
Peripherally inserted central catheters (vs. tunneled lines) (13)
Increased time CVC is in place, especially over 4 years (14)
Multi-lumen CVC (vs. single lumen) (15)
Polyurethane CVC material (vs. silicone estomer) (16)
Blind approach technique for insertion (vs. ultrasound guidance) (17)
CVC, central venous catheter; VTE, venous thromboembolism.
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the current knowledge of risk factors regarding CVC-associated 
VTEs and thromboprophylactic interventions in order to provide 
the first steps toward creating guidelines to prevent thrombosis.
MeTHODS
Search Strategy
We identified English articles using Medline (1975–August 2016) 
and Scopus (1975–August 2016). The search strategies comprised 
“venous thromboembolism,” “risk,” “children,” central venous 
line, central venous catheter, and venous access device, with 
multiple subject headings and text words per concept. Selectively 
exploding subject headings, with relevant subcategories, permit-
ted ever-increasing specificity. We included systematic reviews, 
meta-analyses, randomized controlled trials, prospective cohorts, 
and retrospective cohorts. Case reports and case series were 
excluded.
Study Selection
We excluded studies of patients older than 21 years based on the 
definition of pediatric age from the National Institute of Child 
Health and Human Development. For studies that included 
pediatric and adult patients, we excluded those without clear 
sub-analyses for patients under 21 years. Similarly, we excluded 
studies on arterial thromboembolism unless cases of VTE were 
included and clearly delineated in sub-analyses. Studies were 
identified as narrative reviews, commentaries, single case reports, 
retrospective case series, cross-sectional studies, case–control 
studies, cohort studies (retrospective and prospective), registry 
studies, or clinical trials, the first three of which were excluded.
This review included only pediatric CVC-related VTE with an 
aim to identify additional risk factors and populations at risk. An 
overview of the literature regarding different types and locations 
of CVCs, populations at risk, and prophylactic mechanisms will 
be discussed.
ReSULTS
CvC Data
Incidences of CVC-VTE in children reported in the literature 
vary largely, ranging between 0 and 74% for patients with 
CVCs (4). This variation is explained by differences in study 
design and characteristics of the study populations, such as age, 
underlying diseases, purpose of the CVCs, and use of prophy-
lactic anticoagulation. Most importantly, reported incidences of 
CVC-VTE depend on clinical awareness and the diagnostic test 
used to investigate for VTE. Incidences of CVC-VTE in children 
identified through clinical diagnosis were 4–13% (5–7), through 
venous ultrasonographic screening were 1–44% (5), and screen-
ing via venography were 13–50% (6–8). Table 1 highlights CVC 
characteristics that may lead to an increased VTE rate.
CVC Types and Insertion Locations
There are three distinct types of catheters: non-tunneled, which 
includes peripherally inserted central catheters (PICCs) and acute 
short-term lines; tunneled (Broviacs and Hickmans); and totally 
implanted CVCs (port-a-caths). The ideal type of CVC to mini-
mize CVC-VTE is unknown. Although the populations described 
in systematic reviews and meta-analyses are heterogeneous in 
terms of patient location [e.g., neonatal or pediatric intensive care 
unit (ICU)] or underlying diagnoses (e.g., malignancy, sepsis), 
identification of additional risk factors (risk stratification) has not 
been carried out. As a result, determining the sole impact of the 
catheter type/location to the development of CVC-VTE is chal-
lenging. Furthermore, differing statistical analysis within studies 
of similar patient cohorts makes comparison of results across 
studies challenging. In a systematic review, 15,979 children with 
CVC were reviewed (18). Of all locations of CVCs implanted, the 
incidence of thrombosis was 1.7% [95% confidence interval (CI): 
0.8–2.8]; however, the highest incidence was in umbilical CVCs 
3.7% (CI: 0–12.2) and non-tunneled CVCs 3.7% (CI: 0–11.1). The 
lowest incidence of CVC-VTE was in tunneled lines [0.6% (CI: 
0.2–1.2)] (18). In contrast, a meta-analysis by Vidal et al. (19), the 
frequency of thrombosis per 1,000 catheter days demonstrated 
PICCs, umbilical, and non-tunneled catheters as having the low-
est frequency of CVC-VTE, 0.14–0.18, and tunneled catheters 
having the highest frequency, 0.28. The frequency of CVC-VTE 
was similar in the upper, 0.24 (CI: 0.17–0.31) and lower extremi-
ties, 0.2 (CI: 0.13–0.27) (19), although a trend toward increased 
CVC-VTE in femoral and subclavian insertion is reported with a 
recommendation for jugular vein insertion (11).
CVC Composition and Insertion Technique
There are varied catheter compositions, although polyurethane 
and silicone elastomer is typically used, with silicone catheters 
reported to be the least thrombogenic (16). There was no dif-
ference between antibiotic-impregnated or heparin-bonded 
catheters in the incidence of CVC-VTE (20). With respect to 
CVC diameter and patient age, there are conflicting relationships 
reported between jugular diameter and patient height, weight, 
age, and body surface area (21). The use of a 6Fr/2 mm CVC in 
patients <1 year of age was associated with complications in one 
study (22). Multiple lumen catheters are associated with increased 
occurrence of CVC-VTE, which may be due to the larger size of 
multi-lumen CVCs vs. a single lumen CVC (15, 23).
In terms of insertion technique among adults, ultrasound-
guided approach vs. blind approach to line insertion resulted 
in decreased complications (17). Although not well defined, 
TABLe 2 | Disease states that lead to an increased rate of  
CvC-associated venous thrombosis in children.
Primary disease states with an increased vTe incidence
• Malignancy with any type of CVC. For patients with a port-a-cath: increased 
risk in younger females with left-sided CVCs placed for a prolonged duration
• Neonates in an intensive care unit
• Critically ill children, especially those with a CVC-associated bloodstream 
infection or requiring mechanical ventilation
• Congenital heart disease
• Systemic infection
• Intestinal failure requiring total parental nutrition
• Trauma, especially those with a high injury severity score, received a blood 
product transfusion or an adolescent
VTE, venous thromboembolism; CVC, central venous catheter.
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experts recommend ultrasound-guided approach to line 
insertion (24–26). In a pediatric study of patients with acute 
lymphoblastic leukemia, a percutaneous insertion technique 
was shown to have an increased incidence of CVC-VTE over 
cut-down technique (12).
Patient Data
Venous thromboembolism in children can also occur as a sec-
ondary complication of severe primary diseases (Table 2). The 
most important exogenous risk factor is the presence of a CVC. 
Mahajerin et al. completed a systematic review and meta-analysis 
of risk factors and risk assessment models using case–control 
and non-case–control studies identifying five independent risk 
factors for VTE in pediatric hospitalized patients (27). The most 
significant risk factor for all hospital-acquired VTE (HA-VTE) 
was a CVC presence, followed by the following populations: those 
with systemic infection, ICU admission, mechanical ventilation, 
and prolonged hospital stay. HA-VTE was more prevalent in 
males than females (0.55) in non-case–control studies, which is 
consistent with the results found by Raffini et al. in the Pediatric 
Health Information System Data Base (1). Additionally, there 
is a bimodal age pattern in pediatric patients, revealing a peak 
incidence in neonates and then the adolescent age group. CVC-
VTEs are more likely to occur in neonates, whereas non-CVC-
VTEs are more likely to occur in adolescents (28). Populations 
reported to be at the highest risk for CVC-VTE include those with 
malignancy, sickle cell disease, congenital heart disease (CHD), 
chronic total parental nutrition (TPN) use, and trauma. Other 
patients shown to be at an increased risk for CVC-VTE are those 
with metabolic disorders, renal disorders such as nephrotic syn-
drome and kidney failure requiring dialysis, and those with cystic 
fibrosis (28–30). We will discuss in detail those at the highest risk 
for CVC-VTE.
Children with Hematologic and Malignant Disease
The pathogenesis of thrombosis in patients with cancer is multi-
factorial. This includes the affect of the disease, in which tumor 
cells interfere with the hemostatic system by secreting procoagu-
lant molecules and cytokines, as well as the invasion or compres-
sion of blood vessels my malignant cells (29). Chemotherapeutic 
agents are also highly thrombogenic, including asparaginase, 
which causes antithrombin deficiency and steroids which increase 
factor VIII/von Willebrand factor complex (30). However, the 
most important risk factor is the presence of a CVC, which is 
composed of thrombogenic material and obstructs venous flow 
and irritates the vessel wall (31). In a single-center study, children 
with malignancy and a port-a-cath, younger age, female sex, 
prolonged duration of a port-a-cath, and a left-sided device were 
independent risk factors for CVC-VTE (32).
Sickle cell disease has been demonstrated to have features 
associated with hypercoagulability, including increased levels of 
endothelial and platelet microparticles (33). Patients with sickle 
cell disease also have long-term CVCs, multiple hospitalizations, 
infections, and need for surgeries, thus increasing their risk for 
VTE. However, the reported incidence in retrospective studies for 
CVC-VTE is 0.2%, less than other high-risk populations (34, 35).
Critically Ill Neonates and Children
In a recent review, Park et al. reported an incidence of 9.2% of 
CVC-VTE in patients in the neonatal ICU (36). Alternatively, 
the rate of CVC-VTE was found to be 1.4 per 1,000 hospitalized 
neonates with CVC being an independent risk factor with a 0.9% 
risk (15). Fifty percent of children in PICUs have a CVC with a 
reported incidence of 0.8% symptomatic VTE (37). Children with 
CVC-VTE in the PICU had a median of 1 additional risk factor 
in addition to having a CVC (37), with catheter-associated blood 
stream infection being the most common presenting symptoms 
of CVC-VTE (38). Higgerson et al. in a prospective study with 
11 pediatric ICUs identified other independent risk factors for 
thrombosis including mechanical ventilation and odds ratio 
(OR) 2.8 (CI: 0.98–7.93) (3).
Children with CHD
Children with CHD often have disruptions in the balance of 
hemostasis, which paradoxically could result in bleeding, throm-
bosis, or both. Cyanotic CHD is more commonly reported to 
have known hemostatic abnormalities compared with acyanotic 
CHD. Reported differences include abnormalities in coagulation 
proteins, platelets number and function, and red cell number and 
function altering hemostasis. These abnormalities can result in 
bleeding and/or thrombosis, with many having >1 abnormalities 
present (39). The reported incidence of symptomatic and asymp-
tomatic CVC-VTE in children with CHD and CVC is 28% (40). 
Superior vena cava syndrome resulting from CVC-VTE is a 
serious consequence for children with CHD inhibiting further 
surgical palliation and may be life threatening.
Children with Systemic Infection
Systemic infection has been identified as an additional risk factor 
in all high-risk populations, although no studies have specifically 
evaluated systemic infection and CVC-VTE. However, in severe 
sepsis, dysregulation of the hemostatic system may lead to dis-
seminated intravascular coagulation and result in micro-vascular 
thrombosis that may contribute to CVC-VTE (41). In addition, 
sepsis has been associated with the development of neutrophil 
extracellular traps (NETs), which are composed of extruded 
chromatin, which is negatively charge. The NETs are responsible 
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for killing micro-organisms but have also been found to be highly 
prothrombotic (42). More studies in this area are needed.
Children with Intestinal Failure
One retrospective study reported 53 children with intestinal 
failure (43). Thirty subjects had venous imaging, and 57% of the 
imaged children had at least one symptomatic CVC-VTE with a 
mean of 5.6 ± 3.8 (range 1–12) CVCs per patient. CVC failure 
occurred in 53% of subjects, but there was not a significant dif-
ference in VTE rates in subjects who had a catheter occlusion 
or bloodstream infections and those that did not. By contrast, 
another study evaluating children on home TPN with inflamma-
tory bowel disease were reported to only have an incidence of 
CVC-VTE of 10% (44).
Children after Traumatic Injury
The presence of a CVC continues to be the single greatest risk fac-
tor for VTE in pediatric trauma patients (OR 64, CI: 68.8–243.9) 
with a reported incidence of 0.2% for symptomatic CVC-VTE 
(45). Sixty-seven percent of VTE in trauma patients is at the site 
of the CVC (46). The combination of older age and increased 
injuries (increased injury severity score) escalate the risk of 
CVC-VTE (45). Consideration may be given to blood product 
transfusion, which is also reported to increase VTE in trauma 
patients (47). A recent study from the National Trauma Databank 
demonstrated that VTE risk increases in children beginning at 
age 13 and peaks at age 16, increasing to an incidence of 1% at age 
16, independent of other VTE risk factors (47, 48).
CvC-Related vTe Prevention
There are two main categories of prophylactic measures for chil-
dren who are at risk for a CVC-VTE. These include mechanical 
prophylaxis, which consists of graduated compression stockings 
(GCSs) or intermittent pneumatic compression devices (IPCs), 
and pharmacological prophylaxis, such as systemic anticoagula-
tion, ethanol locks, or fibrinolytics.
Mechanical Prophylaxis
Graduated compression stockings and IPCs improve venous 
blood return from the lower extremities by providing circum-
ferential or intermittent pressure. Theoretically, the use of GCSs 
and IPCs may not prevent CVC-VTEs, especially in the upper 
extremity where many CVCs are placed, but there could be some 
benefit by improving overall venous blood flow and activating 
systemic fibrinolysis (49). Many children will not have access to 
mechanical prophylaxis due to size constraints of the devices. 
Unfortunately, studies have not been conducted in pediatric 
patients to determine if either modality is beneficial, but system-
atic reviews in adults have shown that both the use of GCSs or 
IPCs can prevent VTE (50, 51).
Thromboprophylaxis
Studies regarding the efficacy and safety of prophylactic anticoag-
ulation in pediatric patients are limited. Meta-analysis on the use 
of antithrombotic agents (unfractionated heparin, low molecular 
weight heparin, warfarin, and antithrombin concentrate) and 
nitroglycerin did not demonstrate any significant efficacy with 
prophylaxis of CVC-VTE, although the studies were underpow-
ered and closed early due to poor accrual (19).
Ethanol Locks
Ethanol lock therapy has been demonstrated to decrease the 
rate of central venous line-associated blood infections (CLABSI) 
in a number of pediatric populations with CVC. There are no 
anticoagulant properties associated with ethanol; however, 
ethanol decreases infection and there may be an interrelationship 
between bacteremia and CVC-VTE (52).
Lytic Locks
Tissue plasminogen activator (TPA) is the main fibrinolytic 
drug used for clot lysis and restoration or maintenance of 
catheter patency. A literature review focusing on pediatric 
patients with CVCs and the use of TPA revealed that 50–90% of 
catheters were cleared of thrombosis when TPA was instilled, 
with improved efficacy when doses where higher and dwell 
times were longer (53). Unfractionated heparin has also been 
used to maintain and improve catheter patency. A prospective 
cross-over controlled trial compared TPA to UFH in prevent-
ing CVC-VTE in patients receiving dialysis found TPA to be 
superior for VTE prevention (54).
SUMMARY
Venous thromboembolism is a serious and potentially life-
threatening condition that has lead to increased morbidity and 
mortality in pediatric patients. CVCs remain a predominant risk 
factor for VTE in children, and their use and rate of insertion 
continue to climb. Data evaluating the incidence and specific risk 
factors for CVC-VTE with various CVC types and medical condi-
tions are limited. Most studies are predominantly retrospective, 
single institution, and focused on a single central catheter type. 
This article sought to provide a brief review of the literature 
regarding pediatric CVC-related VTE in order to highlight vari-
ous risk factors linked to catheter characteristics and the patients’ 
medical history.
The overall incidence of CVC-VTE in pediatrics varies greatly 
due to differences in patient population, catheter type, detection 
methods (screening vs. requiring clinical symptoms), and imag-
ing modality. CVC type and its effect on VTE incidence remain 
the most significant question. PICCs, which are usually placed 
into vessels of smaller caliber with a longer intravascular course, 
are being placed even more readily than other forms of CVCs 
(55). Therefore, truly understanding the VTE risk associated 
with PICCs vs. other CVCs is of great importance. Although the 
study results vary, increased CVC-VTE incidence has been found 
with externally tunneled CVCs over implanted CVCs, PICCs and 
umbilical lines over tunneled lines, CVCs placed in the subclavian 
and femoral vein, lines placed in the upper left side, multi-lumen 
CVCs, lines inserted without ultrasound guidance, and CVCs 
made from polyurethane over silicone.
Various patient populations have been shown to have an 
increased risk of VTE. There is difficulty determining if these 
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populations are more at risk for VTE overall or CVC-related 
VTE specifically. Children with the highest risk of CVC-VTE 
are those with malignancy, systemic infection, CHD, gastroin-
testinal failure, sickle cell disease, those in an ICU, and those 
with a traumatic injury. Besides having a CVC, some of these 
patients have many other compounding risk factors, such as 
being in an inflammatory state, having decreased mobility, and 
being exposed to thrombogenic medications such as steroids or 
asparaginase.
Preventative measures, such as mechanical or pharmacological 
prophylaxis, have not been largely studied in pediatric patients, 
and thus, their utility in CVC-VTE prevention is unknown. 
Recurrent TPA locks have been shown to improve catheter flow 
in patients with CVCs obstructed by thrombosis.
In conclusion, our review illustrates the need for large prospec-
tive pediatric studies to truly evaluate catheter types, insertion 
techniques, and clinical characteristics to create guidelines for 
our patients prior to receiving a CVC. We hope that this review 
of the current literature will lead to a better understanding of 
the risk factors linked with CVC-VTE, which will promote the 
needed prospective evaluation.
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